Biora Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Biora Therapeutics' Q3 2024 report reveals a net loss of $16.1 million for the nine-month period, alongside significant financial restructuring and ongoing concerns about the company's ability to continue as a going concern.
Biora Therapeutics reports a net income of $6.5 million for Q2 2024, driven by gains on warrant and derivative liabilities, while facing going concern doubts due to insufficient cash to fund operations for the next 12 months.
Biora Therapeutics reports a net loss of $4.2 million for Q1 2024 and expresses substantial doubt about its ability to continue as a going concern.